title: [Side effects evaluation of ionizing radiation].
abstract: Ionizing radiation is frequently used for cancers with a curative intent for many patients. The total dose delivered on the tumour plays a major factor for locoregional control. Increasing the dose to the tumour volume is generally correlated with an increased dose to normal tissue. Dose constraints to organs at risk must be taken into account for the planning of external beam radiation. A high dose will generate more acute and late side effects. Medical doctors should record these toxicities prospectively. Registration and grading should be simple, reproducible and sensitive in order to obtain an accurate and appropriate evaluation for each organ. Several scales have been published in the literature (WHO, EORTC/RTOG, LENT-SOMA, NCI CTCAE) but none have a satisfactory level. The National Cancer Institute has proposed several version of the CTCAE and its latest version 4.0, currently appears to be the most adapted. The advantage of using only this common and universal classification will be to harmonize practices and have a common language.
authors.affiliation: Service Corad, Pôle Henry-S-Kaplan, CHU Bretonneau, 2 Boulevard Tonnellé, 37044 Tours, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Pointreau
authors.forename: S
authors.initials: S
authors.lastname: Kreps
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D009928:Organ Specificity; D011832:Radiation Injuries / Q000145:classification / Q000209:etiology*; D011839:Radiation, Ionizing; D011878:Radiotherapy / Q000009:adverse effects / Q000145:classification; D011879:Radiotherapy Dosage
chemical_list: D000970:Antineoplastic Agents